Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
16 okt 2013 - 07:38
Statutaire naam
Galapagos NV
Titel
Galapagos to present Phase 1 data on FFA2 antagonist GLPG0974 at UEG Week in Berlin
Bericht
Mechelen, Belgium; 16 October 2013 - Galapagos NV (Euronext: GLPG) announced today that the Company will present in vitro and Phase 1 data showing potent and selective inhibition of FFA2 by GLPG0974 at the United European Gastroenterology Week, taking place from 12 to 16 October 2013 in Berlin, Germany. "The FFA2 antagonist GLPG0974: Opportunity to treat neutrophil-driven inflammation" will be presented on 16 October from 9 am to 2 pm CET and has been granted Poster of Excellence designation from the UEG Week Scientific Committee. The poster is also now available online at www.glpg.com.
Datum laatste update: 17 februari 2025